To visit the Global Nebido® website, please choose from the options below:
Abraham Morgentaler, MD, FACS, gives an overview of functional hypogonadism, the most common causes of which are obesity and type 2 diabetes. Two patient cases are discussed.
Questions addressed in the presentation include:
Goals of testosterone therapy?
Who is a candidate for treatment?
Is there a therapeutic target level?
Do behavioral interventions help?
Treatment and monitoring
Abraham Morgentaler, MD, FACSPast President, Androgen SocietySenior Editor, Androgens: Clinical Research And TherapeuticsAssociate Professor Of UrologyHarvard Medical School
Prof. Geoff Hackett
Dr. Janine David
Prof. Mathis Grossmann
Copyright © 2021, Bayer AG
This website contains information on Nebido® (testosterone undecanoate) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission.
This website is intended to provide information to an international audience outside Austria, France, Germany, Hungary, Ireland, the Middle East, the Philippines, Thailand, the UK, and the USA.
Page last modified 01/04/2021
PP-NEB-ALL-0222-1 April 2021